Oncodesign Precision Medicine (FRA:ZR8) Common Stock: €1.85 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZR8 Oncodesign Precision Medicine SA FRA:ZR8
38 GF Score
Price €0.30
GF Value €0.25
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Common Stock?

Oncodesign Precision Medicine FRA:ZR8 +1.69% 38 Common Stock is €1.85 Mil as of Dec. 2025. GuruFocus rates FRA:ZR8 with a GF Score™ of 38/100 and a GF Value™ of €0.25 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Oncodesign Precision Medicine's quarterly common stock declined from Dec. 2024 (€6.22 Mil) to Jun. 2025 (€1.82 Mil) but then increased from Jun. 2025 (€1.82 Mil) to Dec. 2025 (€1.85 Mil).

Oncodesign Precision Medicine's annual common stock increased from Dec. 2023 (€5.70 Mil) to Dec. 2024 (€6.22 Mil) but then declined from Dec. 2024 (€6.22 Mil) to Dec. 2025 (€1.85 Mil).

Oncodesign Precision Medicine Common Stock Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Common Stock Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.00 5.68 5.70 6.22 1.85

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.70 6.22 6.22 1.82 1.85
FRA:ZR8
38GF Score
Oncodesign Precision Medicine SA FRA:ZR8
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €1.85 Mil mean?
Oncodesign Precision Medicine (FRA:ZR8) has a Common Stock of €1.85 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Common Stock too high?
Oncodesign Precision Medicine's current Common Stock is €1.85 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Common Stock compare to VRTX and REGN?
Oncodesign Precision Medicine's Common Stock of €1.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Common Stock is €1.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.25, compared to a current price of €0.30 — trading 20% above its estimated fair value. The current Common Stock is €1.85 Mil. Oncodesign Precision Medicine's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Common Stock is €1.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.30 is trading 20% above its estimated GF Value™ of €0.25. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for FRA:ZR8:

  • Common Stock: €1.85 Mil
  • GF Value™: €0.25 vs. price of €0.30 (20% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ALOPM:France
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
38GF Score

Get the complete analysis for FRA:ZR8

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.25
GF Value